Xenetic Biosciences Inc. Drops the Corporate Jargon and Gets Real: A Virtual Investor Update That Won’t Put You to Sleep!

Welcome to the Wonderful World of Immune-Oncology Technologies! Positive Preclinical Data Unveiled by Xenetic Biosciences Picture this: Dr. Reid Bissonnette, the Executive Consultant for Translational Research and Development at Xenetic Biosciences, striding confidently onto the virtual stage to share some groundbreaking news with investors like a modern-day superhero. What’s the news, you ask? Well, hold…

Read More

Top-Ranked Law Firm, Rosen, Urges Clients to Meet Important Deadline: A Crucial Reminder from Regn

Important Information for Regeneron Pharmaceuticals Securities Holders: Class Action Lawsuit and Deadline Reminder New York, NY – The Rosen Law Firm, a global investor rights law firm, is reminding purchasers of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) securities between November 2, 2023, and October 30, 2024, both dates inclusive (the “Class Period”), of the significant March…

Read More

Class Action Alert for Block, Inc. (XYZ) Investors: Consider Filing a Lawsuit for Losses – Levi & Korsinsky Invites You to Discuss Your Options

Class Action Lawsuit Filed Against Block, Inc.: What Does It Mean for Investors and the World? On February 21, 2025, Levi & Korsinsky, LLP announced the filing of a class action securities lawsuit against Block, Inc. (NYSE: XYZ). The complaint alleges securities fraud against the Company and certain of its executives, claiming they made false…

Read More